A novel self-lipid antigen targets human T cells against CD1c(+) leukemias

T cells that recognize self-lipids presented by CD1c are frequent in the peripheral blood of healthy individuals and kill transformed hematopoietic cells, but little is known about their antigen specificity and potential antileukemia effects. We report that CD1c self-reactive T cells recognize a nov...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of experimental medicine Vol. 211; no. 7; pp. 1363 - 1377
Main Authors Lepore, Marco, de Lalla, Claudia, Gundimeda, S Ramanjaneyulu, Gsellinger, Heiko, Consonni, Michela, Garavaglia, Claudio, Sansano, Sebastiano, Piccolo, Francesco, Scelfo, Andrea, Häussinger, Daniel, Montagna, Daniela, Locatelli, Franco, Bonini, Chiara, Bondanza, Attilio, Forcina, Alessandra, Li, Zhiyuan, Ni, Guanghui, Ciceri, Fabio, Jenö, Paul, Xia, Chengfeng, Mori, Lucia, Dellabona, Paolo, Casorati, Giulia, De Libero, Gennaro
Format Journal Article
LanguageEnglish
Published United States The Rockefeller University Press 30.06.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:T cells that recognize self-lipids presented by CD1c are frequent in the peripheral blood of healthy individuals and kill transformed hematopoietic cells, but little is known about their antigen specificity and potential antileukemia effects. We report that CD1c self-reactive T cells recognize a novel class of self-lipids, identified as methyl-lysophosphatidic acids (mLPAs), which are accumulated in leukemia cells. Primary acute myeloid and B cell acute leukemia blasts express CD1 molecules. mLPA-specific T cells efficiently kill CD1c(+) acute leukemia cells, poorly recognize nontransformed CD1c-expressing cells, and protect immunodeficient mice against CD1c(+) human leukemia cells. The identification of immunogenic self-lipid antigens accumulated in leukemia cells and the observed leukemia control by lipid-specific T cells in vivo provide a new conceptual framework for leukemia immune surveillance and possible immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
M. Lepore, C. de Lalla, and S.R. Gundimeda contributed equally to this paper.
ISSN:0022-1007
1540-9538
DOI:10.1084/jem.20140410